Gilead Sciences (GILD) to Release Quarterly Earnings on Tuesday

Gilead Sciences (NASDAQ:GILD) is expected to release its Q4 2025 results after the market closes on Tuesday, February 10th. Analysts expect Gilead Sciences to post earnings of $1.87 per share and revenue of $7.68 billion for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 10, 2026 at 4:30 PM ET.

Gilead Sciences Trading Up 0.7%

NASDAQ:GILD opened at $142.89 on Tuesday. The company has a market capitalization of $177.28 billion, a P/E ratio of 22.15, a P/E/G ratio of 0.74 and a beta of 0.36. The stock’s 50 day moving average price is $125.71 and its 200 day moving average price is $119.97. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $143.80.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. HSBC increased their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. The Goldman Sachs Group boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. Morgan Stanley decreased their price target on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Finally, Rothschild & Co Redburn raised their price objective on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the sale, the chief executive officer owned 566,698 shares of the company’s stock, valued at $76,504,230. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the transaction, the executive vice president directly owned 43,676 shares in the company, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 257,397 shares of company stock worth $33,385,512 in the last ninety days. 0.27% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Centaurus Financial Inc. lifted its stake in shares of Gilead Sciences by 20.1% in the third quarter. Centaurus Financial Inc. now owns 6,992 shares of the biopharmaceutical company’s stock valued at $776,000 after buying an additional 1,168 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Gilead Sciences by 135.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 713 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 410 shares in the last quarter. Financial Engines Advisors L.L.C. raised its holdings in Gilead Sciences by 12.8% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 3,147 shares of the biopharmaceutical company’s stock valued at $349,000 after acquiring an additional 358 shares in the last quarter. OmniStar Financial Group Inc. lifted its position in shares of Gilead Sciences by 107.8% in the 3rd quarter. OmniStar Financial Group Inc. now owns 31,073 shares of the biopharmaceutical company’s stock worth $3,449,000 after acquiring an additional 16,117 shares during the period. Finally, Keystone Financial Group grew its holdings in shares of Gilead Sciences by 28.8% during the 3rd quarter. Keystone Financial Group now owns 4,432 shares of the biopharmaceutical company’s stock worth $494,000 after purchasing an additional 990 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.